{"name":"TiGenix n.v.","slug":"tigenix-n-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ChondroCelect implantation","genericName":"ChondroCelect implantation","slug":"chondrocelect-implantation","indication":"Symptomatic cartilage defects of the knee (Grade III-IV, ICRS classification)","status":"phase_3"}]}],"pipeline":[{"name":"ChondroCelect implantation","genericName":"ChondroCelect implantation","slug":"chondrocelect-implantation","phase":"phase_3","mechanism":"ChondroCelect is an autologous cultured chondrocyte implant that replaces damaged cartilage by transplanting the patient's own expanded cartilage cells into the defect site.","indications":["Symptomatic cartilage defects of the knee (Grade III-IV, ICRS classification)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPQjJ2VUhMM1Q5LUpUZWtQbERDaUNmenM4b3htblk1Slk2eHdpRjVoNk5iWHZzZ2NBWkNlUi1SUFZacERUaHBRemU5cFdGSUk5b3JaeTFsYnM4VUxrd0ZoVFRpUEw1bE5VcjU5ZG9FUjc3dkNSZHNxTzNFR2VSR0xfQmNsbw?oc=5","date":"2025-10-07","type":"pipeline","source":"BioWorld News","summary":"Takeda ditches cell therapy business - BioWorld News","headline":"Takeda ditches cell therapy business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxObVlxc3U4MFpkUTZaMmVVWTFRVmV0dkxWei1lUF9qdTJNMGpIaTREdFJQTlZzWVBTMFJBRlF5YXpWX1k2ak5NT2J3elIwLUMtOFUtZGF1ZzFmYVIyaWd2Z3pmMzdTb1FqSjhZemdLaUlnRVQxMlRta0cyMGI0Uko5c2pwWEdUQ1ZzV1BZ0gGQAUFVX3lxTE02UWVvN05VYTI4cjVKWTlCMEtjR2hIX2IyQ1NtVTlVOTV0WTdSMzhFUDM1YnM5VDlMM2N6d052R2tPTWRvVWVXZVQ3Vk5kY05KbVNDNkZtamV3ckw3eDhmQWVKWjVHZXZDNWJMMEUwTGR5QVJJRTc5ckc0R05wNm00TWVHc3F4cm1kMmhxdmIweg?oc=5","date":"2024-11-12","type":"pipeline","source":"BioInformant","summary":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies? - BioInformant","headline":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNTVVGWFpBVkRpTEJWR09RZlI3dHRCWHlQSWkzWUw4ZVhGYlQ2ZkdsV0JzQ2RUM2stbkZGZk5ucklTc3c0NUhUbEpuVHQtdHRLYkNraFpIYlVmV1Q1LTlwWkZON3BCNHd4NUF6LWFmMnNzc2Y3eGh5ODVFUHdZUzhhU3NSWmc0R3ZHeENjZmVDY0pod0pBSkpsa0NYUUk5aUQ1OTA1RmRjaE90dVhaZXV5VHlVQlNFY3RUeW9XYm9NZ0JBM3IxWkFHaXZOSQ?oc=5","date":"2018-04-26","type":"pipeline","source":"The Japan Times","summary":"Shire bid marks Takeda's latest and biggest push for global status - The Japan Times","headline":"Shire bid marks Takeda's latest and biggest push for global status","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxON3U4dkZMRzVPdUJ6LXZ5V3JqVXEtZS1WZTNvQ0s4eVRoSWRBdzFwR1NxcFM0VUp3cS1QVzBsOGo2VjN0d3lyS3psUzRCei16NVYwVWVqN2xkM01FVlA3Y2hfN0NZeVo4dmlNeTdBbFhrOVlCeU5NLWFOM05hRTFGV3pXdzZEa2h6Q1lDNTRlOGJiZjNSalpvVlZXZmFKTHk3WXNnLWxXeHJ2X2dvNkJ2TWpid1psNngzcVc0?oc=5","date":"2018-04-20","type":"trial","source":"Clinical Trials Arena","summary":"Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease - Clinical Trials Arena","headline":"Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQU0t3bkR5V051dW95aFBjOUFGZW13aVNUTU5SMmJlT2Nnc0xnWXNjallhWTBjM3VpeW9tTXZ6bHVaSVBqR0lVRlQzc2N2MDFWeVdJRWhnVkQ1VEJuX0tRTkd0VGJJQVhBWHl3bnNueXczZlNLMmhjeG1hWXYyekhKRnBzU21JTzFVakZCbTNZUWZ5RU1MZW9wS0c5VTBLNUdoU0FmNFo4c3BjeXVKRXk2M1BCckYtSXVvcFJHYjZ4NkJyUlRmMFJyaFU0R2wwUkJEcTRfVmowOA?oc=5","date":"2018-03-28","type":"regulatory","source":"drugdiscoverytrends.com","summary":"Alofisel (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn’s Disease in Europe - drugdiscoverytrends.com","headline":"Alofisel (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn’s Disease in Europe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPNlcxWkI2ZGh5TTd1bFJ6SXV3c0xyR0dnZWJHUEhsYUdjNlRZQk9WdjlVS2dCQXB2bXFEVTBxc0VjV3Zpa3pXa0h5dXpmd09aeFZCQ0dSTVl1RkJOWUNWNjlwMmI3TVAxX1c4STNBOHl6djhPQWFxRndjT2l4QzdMSmRYbmJwd01XYVdwRndPaEFzcV9tYlRFb2JwR3k5SmNzLWJ1M25fTl9HeDljWGVOSzR0M3dHd3FzRjJScU9keXRlVTNpa0xYSzYta0tlWXB6eWtfWXpGM0VMcmdUSklQUzFQRDBCRGxQS0toTW5KYTJKeTBKMVlqWFdCVUI0TUFQSGhELUJhdVJ4bVFZSFl6Q2pOckMxdw?oc=5","date":"2018-03-23","type":"regulatory","source":"prnewswire.com","summary":"TiGenix and Takeda Announce Alofisel® (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn's Disease in Europe - prnewswire.com","headline":"TiGenix and Takeda Announce Alofisel® (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn's Di","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOU1hyaVV4TVJhcUpZWmxuQVQ1WnBXc0NZUmZsYW5zMUdnckZFS011TVVTSDljcnc0eFh2MWhuZ3IyNmVjdEtWMXdhVWViTnIwZHR4RjBYOGlXSzljZmJXQUd5UVZva1ZjNlVpMHJsZ0M3RjJQUzhjWEVXMjNUcXRpanM3UGtRTEluSkhuUktITUhTdXRIdXc?oc=5","date":"2018-02-21","type":"pipeline","source":"BioPharma Dive","summary":"Takeda surfs a potential $2B Wave of acquisitions - BioPharma Dive","headline":"Takeda surfs a potential $2B Wave of acquisitions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQeWhJWXpwb2RoekdfWGRGRW8teVBQcGhIQUd1MFpaRGVYSUhkUVFsLW9sY3VkSk9WalpNWS00WDNPa1VUZkdBSUhwdS1WSXV3N0I2Wm9Ydk9Ub3gxTXY2Ry1tQW1pN0pZSVhOTUVZUmtFdU01MmQwQXhPY1R1WVdzbnh4NERDWTZkZHNCSWJSMlpWUHhzd2h3X3JRam8zVnlMc1Z3SlJJSEZOSEt4UlFwRDJJdWY?oc=5","date":"2016-12-15","type":"pipeline","source":"Nasdaq","summary":"Nasdaq Welcomes TiGenix NV (Nasdaq: TIG) to The Nasdaq Stock Market - Nasdaq","headline":"Nasdaq Welcomes TiGenix NV (Nasdaq: TIG) to The Nasdaq Stock Market","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}